These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

110 related items for PubMed ID: 12121501

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Chronic hepatitis B treatment: the cost-effectiveness of interferon compared to lamivudine.
    Almeida AM, da Silva AL, Cherchiglia ML, Andrade EI, de Oliveira GL, Acurcio Fde A.
    Value Health; 2011; 14(5 Suppl 1):S24-8. PubMed ID: 21839893
    [Abstract] [Full Text] [Related]

  • 4. Cost-effectiveness of peginterferon alpha-2a compared to lamivudine treatment in patients with hepatitis B e antigen positive chronic hepatitis B in Taiwan.
    Sullivan SD, Veenstra DL, Chen PJ, Chang TT, Chuang WL, Tsai C, Patel K.
    J Gastroenterol Hepatol; 2007 Sep; 22(9):1494-9. PubMed ID: 17716353
    [Abstract] [Full Text] [Related]

  • 5. Cost-effectiveness and cost-utility of the treatment of chronic hepatitis B with peginterferon alfa-2a, interferon alfa, and lamivudine in Lithuania.
    Vanagas G, Padaiga Z, Mickevičienė A.
    Medicina (Kaunas); 2010 Sep; 46(12):835-42. PubMed ID: 21532288
    [Abstract] [Full Text] [Related]

  • 6. Prophylaxis of hepatitis B virus recurrence after liver transplantation.
    Testino G, Borro P, Sumberaz A.
    J Gastrointestin Liver Dis; 2009 Jun; 18(2):139-41. PubMed ID: 19565040
    [No Abstract] [Full Text] [Related]

  • 7. Prevention of hepatocellular carcinoma: the holy grail of hepatitis B treatment.
    Sherman M.
    J Hepatol; 2009 May; 50(5):854-6. PubMed ID: 19303162
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Cost-effectiveness of peginterferon alpha-2a compared with lamivudine treatment in patients with HBe-antigen-positive chronic hepatitis B in the United Kingdom.
    Veenstra DL, Sullivan SD, Dusheiko GM, Jacobs M, Aledort JE, Lewis G, Patel KK.
    Eur J Gastroenterol Hepatol; 2007 Aug; 19(8):631-8. PubMed ID: 17625431
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Cost-effectiveness in hepatitis B.
    Weitzman G, Jacobson I.
    Ann Intern Med; 2005 Nov 15; 143(10):757-8; author reply 758-9. PubMed ID: 16287803
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Economic analysis between entecavir and lamivudine for the treatment of chronic hepatitis B in Hong Kong.
    Lee KK, Wu DB, Chow PY, Lee VW, Li H.
    J Gastroenterol Hepatol; 2012 Jul 15; 27(7):1167-74. PubMed ID: 22141402
    [Abstract] [Full Text] [Related]

  • 16. Applicability of cost-effectiveness analysis to management of chronic hepatitis B.
    Dan YY, Lim SG.
    J Gastroenterol Hepatol; 2007 Sep 15; 22(9):1357-9. PubMed ID: 17716341
    [No Abstract] [Full Text] [Related]

  • 17. Hepatitis B virus resistance to antivirals: clinical implications and management.
    Zoulim F.
    J Hepatol; 2003 Sep 15; 39 Suppl 1():S133-8. PubMed ID: 14708691
    [No Abstract] [Full Text] [Related]

  • 18. Decision analysis model for hepatitis B prophylaxis one year after liver transplantation.
    Saab S, Ham MY, Stone MA, Holt C, Tong M.
    Liver Transpl; 2009 Apr 15; 15(4):413-20. PubMed ID: 19326401
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.